An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

Documenti analoghi

• Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
  di: Claudio Maffeis, et al.
  Pubblicazione: (2024)
• Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
  di: Chloë Aernouts, et al.
  Pubblicazione: (2024)
• Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
  di: Seoung Hoon Kim
  Pubblicazione: (2026)
• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  di: Wenxiao Fan, et al.
  Pubblicazione: (2025)
• Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
  di: Sarra Smati, et al.
  Pubblicazione: (2024)